ScreenerHero

ANNXAnnexon, Inc.

NAS · US · Healthcare · Biotechnology · annexonbio.com
5.070USD-7.82%Mkt Cap: 961.17M $P/E: —

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap961.17M $
Enterprise Value797.43M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-206.69M $
Revenue/Share—
Last Price5.070 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees92
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.77
PEG—
EV/EBITDA-3.83
EV/Revenue—
P/S—
P/B4.86
EPS (TTM)-1.06
EPS (Forward)-1.08
52W Range
2.03059% of range7.180
52W High7.180 USD
52W Low2.030 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-97.66%
ROA-74.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-186.36M $
CapEx (TTM)137.00K $
FCF Margin—
FCF Yield-12.07%
Net Debt-184.59M $
Net Debt/EBITDA0.89
Balance Sheet
Debt/Equity0.12
Current Ratio5.53
Quick Ratio5.44
Book Value/Sh1.066 USD
Cash/Share1.104 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.71 USD
Upside (mean)+190.2%
Target Range7.000 USD – 27.00 USD
$7.000+190.2% to mean$27.00
# Analysts7
Ownership
Shares Out.189.58M
Float163.79M
Insiders0.42%
Institutions102.49%
Short Interest
Short Ratio7.7d
Short % Float20.06%
Short % Out.18.78%
Shares Short30.77M
Short (prev mo.)29.60M
Technical
SMA 505.356 (-5.3%)
SMA 2005.278 (-3.9%)
Beta1.22
S&P 52W Chg18.16%
Avg Vol (30d)2.97M
Avg Vol (10d)2.60M
Technical Indicators
RSI (14)44.5
MACD-0.0428
MACD Signal-0.0343
MACD Hist.-0.0085
BB Upper5.607 USD
BB Middle5.256 USD
BB Lower4.904 USD
BB Width13.37%
ATR (14)0.3561 USD
Vol Ratio (20d)0.55x